These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32517872)

  • 21. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Audiological monitoring for ototoxic tuberculosis, human immunodeficiency virus and cancer therapies in a developing world setting.
    Harris T; Peer S; Fagan JJ
    J Laryngol Otol; 2012 Jun; 126(6):548-51. PubMed ID: 22459550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis].
    Poka-Mayap V; Balkissou Adamou D; Pefura-Yone EW; Kuaban C
    Rev Mal Respir; 2020 May; 37(5):369-375. PubMed ID: 32278508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa.
    Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
    Am J Audiol; 2020 Jun; 29(2):199-205. PubMed ID: 32320639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.
    Ghafari N; Court R; Chirehwa MT; Wiesner L; Petersen L; Maartens G; Gumbo T; McIlleron H; Ramma L
    Int J Audiol; 2020 Mar; 59(3):219-223. PubMed ID: 31739701
    [No Abstract]   [Full Text] [Related]  

  • 26. Platinum-induced hearing loss after treatment for childhood cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Research protocol: Cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the feasibility of an audiological monitoring program.
    Paken J; Govender CD; Sewram V
    BMC Womens Health; 2017 Dec; 17(1):129. PubMed ID: 29228931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.
    Hong H; Budhathoki C; Farley JE
    Int J Tuberc Lung Dis; 2018 Jun; 22(6):667-674. PubMed ID: 29862952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aminoglycoside Therapy for Tuberculosis: Evidence for Ototoxicity among Tuberculosis Patients in Ghana.
    Owusu E; Amartey BT; Afutu E; Boafo N
    Diseases; 2022 Feb; 10(1):. PubMed ID: 35225862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD009219. PubMed ID: 27669661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hearing loss in children treated for multidrug-resistant tuberculosis.
    Seddon JA; Thee S; Jacobs K; Ebrahim A; Hesseling AC; Schaaf HS
    J Infect; 2013 Apr; 66(4):320-9. PubMed ID: 22960077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic ototoxicity: a review.
    Shine NP; Coates H
    East Afr Med J; 2005 Oct; 82(10):536-9. PubMed ID: 16450683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Pursuit of Preventive Audiology in South Africa: Scoping the Context for Ototoxicity Assessment and Management.
    Khoza-Shangase K; Masondo N
    J Pharm Bioallied Sci; 2021; 13(1):46-60. PubMed ID: 34084048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
    Sogebi OA; Adefuye BO; Adebola SO; Oladeji SM; Adedeji TO
    Auris Nasus Larynx; 2017 Aug; 44(4):404-410. PubMed ID: 27832910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Drug-induced hearing loss as a manifestation of drug-induced ototoxicity].
    Ostroumova OD; Chikh EV; Rebrova EV; Ryazanova AY; Pereverzev AP
    Vestn Otorinolaringol; 2019; 84(4):72-80. PubMed ID: 31579063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.
    van Altena R; Dijkstra JA; van der Meer ME; Borjas Howard JF; Kosterink JG; van Soolingen D; van der Werf TS; Alffenaar JW
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of streptomycin-induced ototoxicity: protocol for a longitudinal study.
    Adeyemo AA; Oluwatosin O; Omotade OO
    Springerplus; 2016; 5(1):758. PubMed ID: 27386243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.